Detalles de la búsqueda
1.
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Cell
; 168(5): 817-829.e15, 2017 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28215705
2.
Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action.
J Biol Chem
; 299(1): 102729, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36410439
3.
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Mol Pharm
; 12(6): 1717-29, 2015 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25853436
4.
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
Bioorg Med Chem Lett
; 25(3): 529-41, 2015 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25556090
5.
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Nat Commun
; 15(1): 466, 2024 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212321
6.
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
J Pharmacokinet Pharmacodyn
; 37(3): 221-42, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20424896
7.
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment.
Cancer Res
; 80(11): 2368-2379, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32265225
8.
NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
Elife
; 82019 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31144617
9.
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.
Mol Cancer Ther
; 17(7): 1441-1453, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29695635
10.
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
Mol Cancer Ther
; 17(3): 638-649, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29282299
11.
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Clin Cancer Res
; 23(18): 5561-5572, 2017 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28606920
12.
An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
Clin Cancer Res
; 21(14): 3252-62, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25862760
13.
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.
Genes Cancer
; 5(3-4): 113-26, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25053989
14.
Structural basis for resistance to diverse classes of NAMPT inhibitors.
PLoS One
; 9(10): e109366, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25285661
15.
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Clin Cancer Res
; 20(2): 456-68, 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24097864
16.
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
Mol Cancer Ther
; 18(11): 2182, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31676543
17.
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
J Med Chem
; 57(3): 770-92, 2014 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24405419
18.
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.
Sci Transl Med
; 5(171): 171ra18, 2013 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23390248
19.
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Cancer Chemother Pharmacol
; 69(4): 1063-9, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22203367
20.
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Cancer Cell
; 20(4): 472-86, 2011 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-22014573